Aptose Biosciences Inc. (NASDAQ:APTO) Receives $36.50 Average Target Price from Analysts

Aptose Biosciences Inc. (NASDAQ:APTOGet Free Report) (TSE:APS) has earned an average recommendation of “Buy” from the six research firms that are covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have covered the stock in the last year is $36.50.

Several equities analysts recently issued reports on APTO shares. StockNews.com downgraded Aptose Biosciences from a “hold” rating to a “sell” rating in a research report on Monday, March 18th. Piper Sandler cut their target price on Aptose Biosciences from $12.00 to $5.00 and set an “overweight” rating on the stock in a research report on Thursday, February 1st.

View Our Latest Research Report on Aptose Biosciences

Aptose Biosciences Trading Down 2.6 %

Shares of APTO opened at $1.51 on Friday. Aptose Biosciences has a 12 month low of $1.36 and a 12 month high of $10.13. The stock has a fifty day moving average price of $1.86 and a 200-day moving average price of $2.37. The firm has a market cap of $23.73 million, a PE ratio of -0.19 and a beta of 1.30.

Institutional Investors Weigh In On Aptose Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. DRW Securities LLC acquired a new stake in shares of Aptose Biosciences during the 4th quarter valued at about $5,158,000. Sigma Planning Corp acquired a new position in shares of Aptose Biosciences during the 3rd quarter worth approximately $408,000. Millennium Management LLC boosted its holdings in shares of Aptose Biosciences by 75.4% during the 4th quarter. Millennium Management LLC now owns 222,930 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 95,796 shares during the last quarter. Annandale Capital LLC boosted its holdings in shares of Aptose Biosciences by 12.7% during the 4th quarter. Annandale Capital LLC now owns 800,000 shares of the biotechnology company’s stock worth $464,000 after purchasing an additional 90,000 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Aptose Biosciences by 13.6% during the 3rd quarter. Renaissance Technologies LLC now owns 496,709 shares of the biotechnology company’s stock worth $296,000 after purchasing an additional 59,575 shares during the last quarter. 1.07% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

(Get Free Report

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Articles

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.